Is Biogen Stock a Buy Now?
Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.
It's an important achievement for Biogen, but oddly enough, the market responded with a shrug. Still, Leqembi could prove instrumental in turning Biogen's fortunes around. The company's stock has been highly volatile in recent years. But is it enough to make the company's stock a buy?
Source Fool.com
Biogen Inc. Aktie
181,10 €
-0,47 %
Die Community zeigt großes Interesse an Biogen Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 283 € für Biogen Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 181.1 €.
